Pressmeddelanden

XNK Therapeutics AB (“XNK”) today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors. The decision will be taken at an extra…

XNK Therapeutics AB (“XNK”) today announced the appointment of Markus Thor as Chief Business Officer, effective September 6^th. He will be member of the company’s management team. Mr….

After an intensive spring with preparation, planning, procurement, and design, the groundwork was laid for constructing a GMP facility that enables the aseptic production of ATMPs and clinical…

XNK Therapeutics AB (“XNK”) today announced that the first patient has been included in a Phase II clinical study to treat patients with Multiple myeloma using XNK’s leading autologous natural…

XNK Therapeutics AB (publ) today held its Annual General Meeting. The annual general meeting was held through advance voting (postal voting) in accordance with temporary legislation. The following…

XNK Therapeutics AB (“XNK”) today announced the appointment of Professor Michael Uhlin as Chief Scientific Officer, effective August 1^st. He will be a member of the company’s…

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Johan Aschan as Chief Medical Officer, effective July 1^st. He will be member of the company’s management team. Dr….

XNK Therapeutics AB (“XNK” or the “Company”), a Swedish clinical stage immunotherapy company treating cancer by developing novel NK cell-based therapies, today announced the completion of a…

XNK Therapeutics AB (“XNK”) held an extraordinary general meeting on March 18, 2021, where the general meeting resolved to change the company category from private to public limited company. The…

XNK Therapeutics AB (“XNK”) today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination…